Score Overview
Explore the 2021 public Archive ranking →
Where Nektar Therapeutics has ranked, year by year
Showing 1 year ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- NKTR
1999: 79.4% · 2021: 48.6% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 60.40 | — |
1 Year2025-09-26 | $ 58.50 | 3.25% |
5 Years2021-09-28 | $ 276.30 | -78.14% |
10 Years2016-09-28 | $ 265.05 | -77.21% |
20 Years2006-09-28 | $ 214.35 | -71.82% |
30 Years1996-09-27 | $ 97.50 | -38.05% |
All Time1994-05-03 | $ 56.25 | 7.38% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1994-05-03 |
|---|---|---|---|---|---|---|---|
| Price | $ 60.40 | $ 58.50 | $ 276.30 | $ 265.05 | $ 214.35 | $ 97.50 | $ 56.25 |
| Return | — | 3.25% | -78.14% | -77.21% | -71.82% | -38.05% | 7.38% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 55M | -$ 158M | $ 568M |
| 2025 | $ 55M | -$ 164M | $ 245M |
| 2024 | $ 98M | -$ 118M | $ 255M |
| 2023 | $ 90M | -$ 276M | $ 303M |
| 2022 | $ 92M | -$ 368M | $ 504M |
| 2021 | $ 101M | -$ 523M | $ 733M |
| 2020 | $ 152M | -$ 444M | $ 1.06B |
| 2019 | $ 114M | -$ 440M | $ 1.32B |
| 2018 | $ 1.19B | $ 681M | $ 1.33B |
| 2017 | $ 307M | -$ 96M | $ 296M |
| 2016 | $ 165M | -$ 153M | $ 389M |
| 2015 | $ 230M | -$ 81M | $ 308M |
| 2014 | $ 200M | -$ 53M | $ 237M |
| 2013 | $ 148M | -$ 162M | $ 237M |
| 2012 | $ 81M | -$ 171M | $ 277M |
| 2011 | $ 71M | -$ 133M | $ 241M |
| 2010 | $ 159M | -$ 37M | $ 315M |
| 2009 | $ 71M | -$ 102M | $ 396M |
| 2008 | $ 90M | -$ 34M | $ 378M |
| 2007 | $ 273M | -$ 32M | $ 482M |
| 2006 | $ 217M | -$ 154M | $ 458M |
| 2005 | $ 126M | -$ 185M | $ 476M |
| 2004 | $ 114M | -$ 101M | $ 418M |
| 2003 | $ 106M | -$ 46M | $ 285M |
| 2002 | $ 94M | -$ 107M | $ 293M |
| 2001 | $ 77M | -$ 250M | $ 344M |
| 2000 | $ 51M | -$ 97M | $ 484M |
| 1999 | $ 41M | -$ 38M | $ 138M |
| 1998 | $ 21M | -$ 18M | $ 82M |
| 1997 | $ 16M | -$ 9M | $ 100M |
| 1996 | $ 6M | -$ 10M | $ 18M |
| 1995 | $ 3M | -$ 7M | $ 3M |
| IPO1994 | $ 1M | -$ 5M | $ 10M |
Nektar Therapeutics fundamental performance
Between 2020 and 2025, revenue declined from $ 152M to $ 55M and net income went from -$ 444M to -$ 164M. Revenue increased in 2 of those 5 years; net income in 4.
Between 2015 and 2025, revenue declined from $ 230M to $ 55M and net income went from -$ 81M to -$ 164M. Revenue increased in 5 of those 10 years; net income in 6.
Nektar Therapeutics currently holds a 20-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.
Membership
Continue NKTR’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
